Newsletter

DIARECT Newsletter November 2019


Summary

 

Dear Madam or Sir,

With more than 5,200 exhibitors and about 120,000 visitors in 2018, this year’s MEDICA will once again be the platform that brings together medical expertise & professional knowledge from experts from all over the world.

As in the past years, DIARECT will exhibit at this world’s largest event for the medical sector in Düsseldorf, Germany, from November 18 – 21, 2019.

It is our great pleasure to present a new version of our catalog. To receive your personal print version you are welcome to stop by our booth D37 in Hall 1. A digital copy including all 2019 product launches is provided for download here.

If you have any product related questions or would like to schedule an appointment, please feel free and contact us at:

Email   info(at)diarect.com 
Tel.     +49 761 47979-0 

We are looking forward to meet with you in Düsseldorf!

DIARECT AG

DIARECT’s Human Chimeric Monoclonal Antibodies: New Packages Sizes Available

The detection of antibodies in patient samples requires reference material to determine cut-off values and test assay integrity. Most often this reference material consists of pools of disease state serum or plasma, but main drawbacks of these standards are their limited availability and variability, and there are also safety and ethical issues. What is required is a virtually unlimited supply of antibodies with a consistent concentration, specificity and avidity.

DIARECT provides human chimeric monoclonal antibodies as standards or positive control reagents for use in IVD kits for autoimmune liver and connective tissue diseases.

We at DIARECT appreciate the feedback of our customers and are pleased to implement suggestions where possible. Therefore, due to increased demand, we now offer all human chimeric monoclonal autoantibodies in 1.0 mg vials as well as the standard 0.1–mg size. Updated brochures are available and a detailed overview of all human chimeric monoclonal autoantibodies can be found below:

 

Human Chimeric Antibodies

 

References:
Cogné et al. (2013) European Patent N°13305964.2

Introduction of Additional Food Allergens

Food and pollen from a species usually comprise more than one allergenic component that may share various degrees of identity and might induce cross-sensitivity to other species due to cross-specific IgE antibodies. Molecular identification of individual allergens and subsequent establishment of Component Resolved Diagnostics (CRD) allow the detection of specific IgE antibodies.

Hazelnut allergy is one of the most common tree nut allergies and can cause symptoms that range from mild to severe.
In Central and North-Western Europe mild cases often are observed in patients allergic to tree pollen, in particular to birch pollen. This so-called oral allergy syndrome (OAS) is a form of food allergy in which people who are sensitive to specific types of pollen also react to certain foods due to cross-specific IgE antibodies. Severe hazelnut allergy is much rarer, independent of tree pollen allergy, and caused by different allergenic components of hazelnut.

CRD is becoming more utilized and may improve accuracy for diagnosing tree nut allergy:

  • Sensitization to PR-10 protein Cor a 1.0401 indicates birch pollen related OAS and is typically associated with local reactions.
  • Sensitization to lipid transfer protein (LTP) Cor a 8.0101 indicates cross-reactivity, often from primary peach sensitization. Local oral symptoms and systemic reactions may occur.
  • Sensitization to 11S globulin-like protein and seed storage protein Cor a 9 indicates primary hazelnut allergy. The presence of IgE antibodies is associated with systemic reactions.
  • Sensitization to 2S albumin and seed storage protein Cor a 14.0101 indicates primary hazelnut allergy. Like Cor a 9 the presence of IgE antibodies against Cor a 14.0101 is associated with systemic reactions.

 

Depending on the geographic region (Spain, USA) walnut allergy is the most common tree nut allergy. Similar to hazelnut, purified walnut allergen components are used for improved risk assessment of patients:

  • Sensitization to 2S albumin and seed storage protein Jug r 1.0101 is associated with severe clinical presentations
  • Sensitization to lipid transfer protein (LTP) Jug r 3.0101 seems to be of special importance in Mediterranean patients. Local oral symptoms and systemic reactions may occur.

 

DIARECT is proud to present new additions to our panel of recombinant and native purified food allergens:

Recombinant Food Allergens

 

References:
Beck et al. (2018) J Clin Patho. 71 (3): 239-245
Canonica et al. (2013) World Allergy Organi J. 6: 1-17
Hansen et al. (2009) J Allergy Clin Immunol. 123 (5):1134-1141
Kattan et al. (2014) J Allergy Clin Immunol Pract. 2 (5): 633-634
Pastorello et al. (2004) J Allergy Clin Immunol. 114 (4): 908-914
Turnbull et al. (2015) Aliment Pharmacol Ther. 41 (1): 3-25
Weinberger and Sicherer (2018) J Asthma Allergy. 11: 41-51
Werfel et al. (2015) Allergy. 70 (9): 1079-1090

Distributors

To facilitate the world-wide sales of our antigens, DIARECT has distribution agreements with select companies.

If you are located in North America, DIARECT’s products are exclusively distributed by:

Surmodics IVD, Inc.
9924 West 74th Street
Eden Prairie, MN 55344
USA
Phone +1 952 500 7200
Toll-free +1 800 755 7793
Fax +1 952 500 7201
orders(at)surmodics.com
www.surmodics.com

If you are located in China, DIARECT’s products are distributed by:

Shanghai BioSun Sci&Tech Co., Ltd.
Room K, 5F, Bldg. No.1
825 Zhaojiabang Road
Shanghai 200032
P.R. China
Phone +86 21 54253791
Fax +86 21 64280007
biosun(at)biosun.cn
www.biosun.cn